Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...
Amphastar Pharmaceuticals, Inc., headquartered ...
Global leader in therapeutic ultrasound and present in the market for more than 35...
Global leader in therapeutic ultrasound and pre...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.